Work

Vedolizumab for Moderate to Severely Active Inflammatory Bowel Disease: A Multicenter U.S. Consortium

Year: 2015

Type: article

Study design: Observational Study

Source: The American Journal of Gastroenterology

DOI: 10.14309/00000434-201510001-01904

Authors: Parambir S. Dulai, Siddharth Singh, Neeraj Narula, Farhad Peerani, Diana A. Whitehead, David Hudesman, Sunanda Kane, Corey A. Siegel, Bruce E. Sands, Jean-Frederic Colombel, Edward V. Loftus, William J. Sandborn, Brigid Boland

Institutions: University of California San Diego, Mayo Clinic, Icahn School of Medicine at Mount Sinai, Dartmouth–Hitchcock Medical Center, New York University

Language: English

Topic: Inflammatory Bowel Disease

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2977854286

FWCI: 0.455

Cites:

Cited by: 3

Related to: 10